

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Alfellani, MA; Stensvold, CR; Vidal-Lapiedra, A; Onuoha, ES; Fagbenro-Beyioku, AF; Clark, CG (2013) Variable geographic distribution of Blastocystis subtypes and its potential implications. *Acta tropica*, 126. pp. 11-18. ISSN 0001-706X DOI: <https://doi.org/10.1016/j.actatropica.2012.12.011>

Downloaded from: <http://researchonline.lshtm.ac.uk/588991/>

DOI: [10.1016/j.actatropica.2012.12.011](https://doi.org/10.1016/j.actatropica.2012.12.011)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Title

Variable geographic distribution of *Blastocystis* subtypes and its potential implications

Authors

Mohammed A. Alfellani^{a,e}, C. Rune Stensvold^b, Amparo Vidal-Lapiedra^c, Emeh Sunday Uche

Onuoha^d, Adetayo F. Fagbenro-Beyioku^d, C. Graham Clark^{a*}

Affiliations

^aPathogen Molecular Biology Department, Faculty of Infectious and Tropical Diseases, London

School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK

^bDepartment of Microbiology and Infection Control, Statens Serum Institut, Artillerivej 5, DK-

2300 Copenhagen S, Denmark.

^cDepartamento de Biología Celular y Parasitología, Facultad de Farmacia, Universitat de

València. Av. Vicent Andrés Estellés s/n c.p: 46100 Burjassot, Valencia, Spain

^dParasitology Unit, Department of Medical Microbiology & Parasitology, College of Medicine,

University of Lagos, P.M.B 12003, Nigeria.

^eDepartment of Parasitology, Faculty of Medicine, Sebha University, Sebha, Libya

*Corresponding author:

C. Graham Clark, Pathogen Molecular Biology Department, Faculty of Infectious and Tropical

Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E

7HT, UK. Tel: +44-20-7927-2351; Fax: +44-20-7636-8739

Email: graham.clark@lshtm.ac.uk

1
2
3
4
5 **Abstract**
6

7 *Blastocystis* is a common intestinal micro-eukaryote found in both humans and non-human hosts
8 and known to be genetically very diverse. It has been divided into numerous subtypes (STs), nine
9 of which have been identified in humans to date. Surveys of ST prevalence have started to
10 emerge over the past few years but to date no data are available for any African country except
11 Egypt and Tanzania. In this study, we determined the prevalence of *Blastocystis* STs in
12 populations from Libya, Liberia and Nigeria, as well as expanding the dataset available for the
13 UK. A total of 356 *Blastocystis* STs were identified in this study, 271 from the UK, 38 from
14 Libya, 25 from Liberia and 22 from Nigeria. SSU rRNA gene sequences revealed the presence of
15 eight of the nine STs known from humans but at varying frequencies between countries. ST1 was
16 the most common ST in Libya and Nigeria whereas ST3 showed the highest frequency in the
17 other two countries, as indeed is the case in most populations around the world. ST4 was absent
18 in Libya and ST2 in Nigeria, while no ST5, ST6, ST8 or ST9 infections were detected in any of
19 the three African populations. The picture emerging from this and other surveys suggests that
20 there is significant variation in ST prevalence between populations. Some of the possible reasons
21 for and implications of this diversity are discussed.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44
45
46 **Keywords:** *Blastocystis*, diversity, epidemiology
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 **1. Introduction**
6

7 *Blastocystis* is a common intestinal parasitic micro-eukaryote with a worldwide distribution and
8 is often the most frequently detected parasite in epidemiological surveys (Clark et al., in press).
9
10 Its prevalence varies from country to country and among various communities within the same
11 country. Generally, however, the prevalence in developing countries is higher than in developed
12 countries, which has been linked to standards of hygiene, waste disposal, exposure to animals,
13 and consumption of contaminated food or water (Tan, 2008), although direct evidence for some
14 of these is lacking.
15
16

17 DNA-based methods have been developed that are able to identify genetic variation between
18 *Blastocystis* organisms that are morphologically indistinguishable under the microscope.
19

20 Molecular studies have focused mostly on determining the prevalence of *Blastocystis* subtypes
21 (STs) in asymptomatic and symptomatic individuals (Böhm-Gloning et al., 1997; Kaneda et al.,
22 2001; Souppart et al., 2009; Stensvold et al., 2011a; Stensvold et al., 2009; Yan et al., 2006;
23 Yoshikawa et al., 2004). In spite of recent methodological advances, the molecular epidemiology
24 of *Blastocystis* infections is still unknown in many parts of the world. Recent studies are starting
25 to provide more information on the distribution of STs among human populations (Tan, 2008;
26 Clark et al., in press) but most have been carried out in temperate regions. To date there is some
27 indication of geographic variation in the prevalence of STs (eg. Forsell et al., 2012a,b) as well as
28 reports of associations between specific STs and disease, although with conflicting conclusions
29 (eg. Domínguez-Márquez et al., 2009; Jones et al., 2009; Stensvold et al., 2011a; Tan et al.,
30 2008).
31

32 In this study our aim is to investigate the distribution of *Blastocystis* STs from unselected
33 individuals in North and West Africa, where climates, cultures and ecological conditions are
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 likely to be quite different from most regions surveyed to date. This will fill a geographic gap in
3
4 our knowledge of *Blastocystis* diversity around the world and also provide an insight into
5
6 whether such variables influence ST distribution. In addition, we greatly expand the data
7
8 available on ST prevalence for the UK.
9
10

11 **2. Materials and Methods**

12 *2.1. Source of specimens*

13
14
15 UK samples: A total of 271 new *Blastocystis* isolates from samples submitted for routine ova and
16
17 parasite analysis were studied; 136 came from Irritable Bowel Syndrome (IBS) clinics in
18
19 England, while the other 135 were submitted by the patient's physician, usually because the
20
21 patient was symptomatic but the cause was unknown. Both sample groups were received through
22
23 the Diagnostic Parasitology Laboratory of the London School of Hygiene and Tropical
24
25 Medicine. The final patient diagnosis is not known and it is likely that some IBS clinic samples
26
27 were from patients later diagnosed with non-IBS causes of their symptoms and, equally, some of
28
29 the physician-submitted samples were likely from patients with IBS. Ethical approval for work
30
31 on the UK samples was obtained (LSHTM reference no.5026).
32
33

34
35 Libya samples: 150 faecal samples submitted for ova and parasite examination by Libyan
36
37 patients attending the Sebha Central Medical Laboratory were studied. The samples were
38
39 submitted in order for the patient to get a health certificate, join the army, or attend university,
40
41 rather than because the patient was symptomatic. 42 (28%) of these samples were positive by
42
43 direct smear and 38 of these grew in culture. The Ethics Committee of Sebha University
44
45 concluded that no specific approval was needed for the further analysis reported here. Sebha is a
46
47 city in southwestern Libya (27°2'0" North, 14°26'0" East) with a population of 130,000. It was
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 historically the capital of the Fezzan region and is now capital of the Sebha District. The weather
4
5 is hot and dry in summer and cold and dry in winter.
6

7
8 Liberian samples: 43 faecal samples from children aged 6-18 from Bomi, Bong and Margibi
9
10 counties, Liberia, were included. These three counties are to the Northwest, Northeast and East
11
12 of the capital Monrovia (6°18'48"North 10°48'5"West), respectively. 30 (70%) of the samples
13
14 were positive for *Blastocystis* by PCR. Informed consent was obtained from the parents or school
15
16 director for analysis of samples from under-age children. Liberia has a hot equatorial climate
17
18 with the rainy season between May to October.
19
20

21
22 Nigerian samples: 47 faecal samples were obtained from Nigerian patients (median age 32 y,
23
24 inter-quartile range: 24-41 y) attending a clinic in Lagos. The Ethics and Experimentation
25
26 Committee of the College of Medicine, University of Lagos PEPFAR/APIN and Lagos
27
28 University Teaching Hospital, concluded that no ethical permission was needed for this work. 23
29
30 (49%) of the samples were positive for *Blastocystis* by PCR. Lagos is a metropolitan city located
31
32 in the southwest region of Nigeria (6°27'11" North, 3°23'45" East). A typical tropical rainforest
33
34 climate exists in the city. The population of Lagos is estimated at over 10 million.
35
36
37
38
39
40
41

42 2.2. Sample processing

43
44 Approximately 50 mg of each Libyan and UK faecal sample was inoculated into Robinson's
45
46 medium (Clark and Diamond, 2002) or (in Libya only) a modification of Jones' medium
47
48 (Leelayoova et al., 2002) using a Luria agar slant and supplemented with 10% human serum. The
49
50 culture was incubated at 37 °C and examined every two days. Positive cultures were passaged
51
52 into fresh medium for another 3-4 days, then *Blastocystis* was harvested by centrifugation and
53
54 the pellet resuspended in lysis buffer for DNA extraction using the Puregene core kit A (Qiagen,
55
56 Crawley, UK) according to the manufacturer's protocol. This rapid DNA extraction prevents the
57
58
59
60
61
62
63
64
65

1
2
3 possibility of differential ST growth affecting subsequent analyses in our experience. DNA of
4
5 samples from Nigeria and Liberia was extracted directly from faeces using the QIAamp DNA
6
7 Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations.
8
9

10 11 12 2.3. PCR amplification and sequencing 13

14
15 PCR amplification of partial *Blastocystis* small subunit ribosomal RNA genes (SSU-rDNA) for
16
17 subtyping of samples from the UK, Liberia and Libya was performed (at LSHTM) in a 40µl
18
19 volume reaction using Biomix (Bioline, London, UK) and the primers BhRDr (5'GAG CTT TTT
20
21 AAC TGC AAC AAC G3') and RD5 (5'ATC TGG TTG ATC CTG CCA GTA3') at 2 µM
22
23 concentration. These primers amplify a 600 bp region of the SSU-rDNA that contains sufficient
24
25 information for unambiguous assignment of STs to samples (Scicluna et al., 2006). The
26
27 following amplification profile was used: 30 cycles of denaturation at 94 °C for 30 seconds,
28
29 annealing at 59 °C for 30 seconds and extension at 72 °C for 30 seconds. PCR products were
30
31 purified using the QiaQuick gel extraction kit (Qiagen, Hilden, Germany) or the GeneJet PCR
32
33 Purification kit (Fermentas, Epsom, UK) and sequenced using the BhRDr primer as described
34
35 previously (Scicluna et al., 2006).
36
37
38
39
40

41
42 Nigerian samples were screened for *Blastocystis* by PCR (at the SSI) using the primers
43
44 b11400ForC and b11710RevC, which amplify a 310 bp SSU-rDNA product, or the primers F1
45
46 and BHCRseq3, amplifying a 550 bp product, and Extract-N-Amp PCR ReadyMix (Sigma–
47
48 Aldrich Denmark, Brøndby, Denmark). PCR products were sequenced as described previously
49
50 (Stensvold et al., 2007; Stensvold et al., 2006).
51
52

53
54 STs were assigned based on the results of BLAST analysis against the databases at NCBI and/or
55
56 www.pubmlst.org/blastocystis. Nucleotide sequences of samples from which unambiguous
57
58
59
60
61
62
63
64
65

barcode sequences were obtained have been submitted to the isolate database at www.pubmlst.org/blastocystis.

3. Results and discussion

3.1. UK samples

The samples from the UK had two distinct origins and could therefore have had distinct ST characteristics: half of the samples were submitted by IBS clinics. The ST profiles of the two sets of samples were compared using the chi-square test. Although there was a clear excess of ST4 in IBS samples, the distribution of STs in the two sample groups did not show any significant difference overall ($p = 0.18$; Table1), so we have combined the two sets of data for geographic comparisons.

The distribution of STs in the UK samples is generally similar to those reported previously in the UK and elsewhere in Europe (Table 2), where ST3 is the most frequently detected ST, followed by ST4, with STs 1 and 2 each having a prevalence of about 10% .

3.2. African samples and comparison with UK samples

In Libya the prevalence of *Blastocystis* has been reported previously to be 26.6% (Alfellani et al., 2007), which is very similar to the prevalence in the current samples (28%). The prevalence of *Blastocystis* in Liberia has not been reported to date and the only report from Nigeria is a prevalence of 2.5% (in Ogun State) using microscopy (Reinthalder et al., 1988).

The only previous reports of ST prevalence in Africa are from three studies conducted in Egypt and a small one in Tanzania (Table 2). Libya, Nigeria, Liberia and Egypt cover a range of distinct climate conditions. Despite this, ST3 was highly prevalent in all countries (ca. 30-60%;

1
2
3 Table 3), although ST1 was detected at the highest frequency in both Libya and Nigeria, with
4
5 50% and 45.5% respectively. In neither the Nigerian samples nor in two of the studies from
6
7 Egypt (Egypt1 and Egypt3; Table 3) was ST2 detected, in contrast to most previous surveys and
8
9 the other three locations sampled in this study.

10
11
12 Despite ST4 being the second most common ST detected in the UK and being quite common in
13
14 both Liberia and Nigeria, in Libya and Egypt it was not detected at all. ST6 and ST7 were both
15
16 found in the UK and ST7 in Libya although rarely. However in Egypt these two STs show a high
17
18 prevalence in two of the published studies (10-25% for each ST in Hussein et al. (2008) and
19
20 Fouad et al. (2011)) despite not being found at all in the other study (Souppart et al, 2010). ST5
21
22 and ST8 were not detected in any African country but this is perhaps not surprising as they are
23
24 rare in all human surveys (<1%).

25
26
27
28
29 The UK distribution showed a significant difference from all the African studies except that in
30
31 Egypt by Souppart et al. (2010), although for the Liberian study the difference, while still
32
33 present, was less striking ($0.05 > P > 0.01$). The Libyan and Liberian distributions showed no
34
35 significant difference from the Nigerian or the Egypt2 (Souppart et al., 2010) distributions,
36
37 although they differed from each other. It is notable that Souppart et al. (2010) differed from the
38
39 other Egyptian studies in using SSU-rDNA sequence-based identification of STs, compared to
40
41 the Sequence Tagged Site (STS) PCR-only approach in the other two. Whether this difference in
42
43 methodological approach has affected the results of the Egyptian surveys is unclear.

44 45 46 47 48 49 50 51 *3.3. Review of Blastocystis subtypes in IBS patients*

52
53
54 Although we found no significant difference between the UK samples submitted by IBS clinics
55
56 and those submitted from other sources, primarily personal physicians, we feel that some
57
58 discussion of ST distribution in IBS patients is worthwhile. There have been three previous
59
60
61
62
63
64
65

1
2
3 studies carried out on the distribution of *Blastocystis* STs in such patients, in Pakistan, Turkey
4
5 and Egypt. Since the number of IBS samples in Turkey (Dogruman-Al et al., 2009a) was only
6
7 five we have limited the comparison with our IBS clinic sample results to the data from Pakistan
8
9 (Yakoob et al., 2010) and Egypt (Fouad et al., 2011) (Table 4).

10
11
12 In Pakistan, ST1 is the most common ST detected in IBS samples, whereas ST3 is the most
13
14 frequent ST in Egypt and the UK. ST4 is the second most frequently detected in the UK (37.5%)
15
16 and is 1.5x more common in IBS compared to other samples (see above). In contrast, ST4 in
17
18 Pakistan makes up less than 5% of IBS samples and in Egypt it was not detected at all.

19
20
21 The non-IBS ('control') *Blastocystis* STs were also compared from the same studies (Table 5).

22
23
24 This time, in all three countries ST3 was the most common ST. Again, in the UK ST4 was the
25
26 second most frequently detected, but in Pakistan ST1 and in Egypt ST6 were the second most
27
28 common STs. In Egypt, ST6 and ST7 were both much more common than in either of the other
29
30 two countries, although even in Pakistan they were more common than in the UK. It is clear that
31
32 no consistent pattern exists between IBS-linked samples and the ST of *Blastocystis* detected
33
34 since the distribution observed is very different in each country.
35
36
37
38
39
40

41 42 *3.4 Aspects of the relative global distribution of Blastocystis subtypes*

43
44 Information on variation in the distribution of STs between geographic locations is only starting
45
46 to emerge and large gaps remain to be filled on the world map. In this study we have partially
47
48 filled one gap, in North and West Africa, by presenting data from Libya, Liberia and Nigeria.

49
50
51 These data can now be compared to those from other regions of the world.

52
53
54 The difference in the relative diversity and prevalence of STs isolated from humans might reflect
55
56 different epidemiological and demographic characteristics including climate, geography, cultural
57
58 habits, exposure to reservoir hosts, and mode of transmission. The ST distribution in the UK
59
60
61
62
63
64
65

1
2
3 population sampled in the present study was quite similar to that found in previous UK studies
4
5 and those from elsewhere in Europe (Table 2). In contrast, ST distributions in the African
6
7 countries showed variable similarity to each other and to studies performed elsewhere in the
8
9 world.

10
11 The three studies carried out in Egypt used different techniques to identify *Blastocystis* STs.

12
13 Hussein et al. (2008) and Fouad et al. (2011) used the STS technique and found similar

14
15 *Blastocystis* ST frequencies (ST1, ST3, ST6 and ST7) even though samples came from different

16
17 cities in Egypt (Cairo and Ismailia). In contrast, Souppart et al. (2010), also sampling in Cairo,

18
19 used sequencing and reported ST distributions quite different from the other two studies (Table

20
21 3). It is not clear whether the choice of methodology has affected the results in any way, but it

22
23 suggests that a comparative study is needed using both techniques on the same Egyptian

24
25 samples. Although Libya has a long border with Egypt and people frequently migrate between

26
27 the two countries, different *Blastocystis* ST distributions are still observed between the two

28
29 populations sampled using sequencing methodology ($p=0.026$).

30
31 ST1 has been suggested by some authors to be linked to zoonotic transmission from farm

32
33 animals (Noël et al., 2005; Tan, 2008). The finding that this ST was the most common in the

34
35 Libyan population might suggest that exposure to animal faeces could be a significant source of

36
37 infection. Many people in Libya keep animals at home, including goats and sheep, or on a family

38
39 farm, such as cows and camels, and they use them for food and milk. However, there is, in fact, a

40
41 low prevalence of ST1 in domestic animals surveyed to date in Libya (Alfellani et al., in

42
43 preparation) so it seems unlikely they are a significant source of infection for humans. In contrast

44
45 ST5 is very common in Libyan domestic animals but was not detected in any human samples

46
47 from that country.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 ST2 also shows evidence of some geographic variation in frequency of detection (Figure 1;
4
5 Table 2). In Africa, Australia and East Asia it is rare, with a detection rate of 7% or less
6
7 compared to over 12% in the other regions with reasonable levels of sampling. Once again,
8
9 however, studies using STS appear less likely to detect ST2 than sequence-based surveys in the
10
11 same regions (Table 2).
12
13

14
15 ST3 is the most prevalent overall in humans (44.1%; Table 2) and is the most commonly
16
17 detected ST in a majority of individual studies. The exceptions are those studies performed in
18
19 Libya, Nigeria, Thailand, Brazil, and one study each from Pakistan, Iran, and Turkey, where ST1
20
21 was the most common; the other exceptions are the studies from Ireland (ST2), Spain (ST4), one
22
23 study from Denmark (ST4) and one study from Nepal (ST7). The study from Spain was
24
25 remarkable, since ST3 was not found at all; however, the majority of the patients had acute
26
27 diarrhoea, and ST4 was similarly found in more than 70% of *Blastocystis* infected patients with
28
29 acute diarrhoea in one Danish study (Stensvold et al., 2011).
30
31
32

33
34 ST4 is the second most common ST in the UK and is commonly found across Europe (Table 2).
35
36 It is not known why ST4 is so common in Europe and much less frequently detected or absent in
37
38 the Far East, South America and North Africa (Table 2). Rodents have been identified as a
39
40 reservoir host of ST4 (Noël et al., 2005; Noël et al., 2003; Silberman et al., 1996; Yoshikawa et
41
42 al., 1998) but exposure to rodent faeces is likely to be almost universal. It is notable that ST4 is
43
44 rare in those studies where ST1 is the most commonly identified and that many studies where
45
46 ST4 is rare or absent were conducted in countries that are subtropical and/or have mostly Muslim
47
48 populations. However, no information on *Blastocystis* STs is available from other North African
49
50 countries, many Middle Eastern countries or India, which means that gaps exist in our
51
52 knowledge of the distribution of *Blastocystis* STs that might allow us to link studies where ST4
53
54 is absent across a large geographical area. It is important to remember that our African ST data
55
56
57
58
59
60
61
62
63
64
65

1
2
3 are limited in both sample number and geography. Only one location was sampled in Libya and
4
5 Nigeria so, for example, we do not know whether the findings from Sebha and Lagos are
6
7 representative of the whole of Libya and Nigeria or whether we would obtain different results in
8
9 different parts of these countries, as in the three studies from Egypt (Table 3).
10
11
12
13
14

15 *3.5 Correlation between Blastocystis subtypes and disease*

16
17 Whether *Blastocystis* has a role in human disease is uncertain because the organism is found
18
19 commonly in both symptomatic and asymptomatic individuals (Clark et al., in press). Although
20
21 many reports have linked *Blastocystis* to gastrointestinal disorders, the clinical importance of this
22
23 organism has not yet been defined. The parasite has been linked with gastrointestinal symptoms
24
25 such as watery and mucousy diarrhoea, vomiting, abdominal cramps and bloating. Some
26
27 epidemiological studies have also suggested a role in IBS (Stark et al., 2007; Ustun and Turgay,
28
29 2006). Since *Blastocystis* infection is more common in IBS patients (Jimenez-Gonzalez et al.,
30
31 2012; Stensvold et al., 2009; Yakoob et al., 2004) and because symptoms linked to *Blastocystis*
32
33 resemble IBS, the possible role of *Blastocystis* in this syndrome needs to be investigated.
34
35
36
37
38

39 We studied the frequency of STs of *Blastocystis* in patient samples submitted from IBS clinics
40
41 with samples from other patients in the UK and compared these results with published data from
42
43 other countries. No consistent link between ST and IBS could be identified across studies in
44
45 three different countries even though in each case a difference was noted between IBS and non-
46
47 IBS samples. This does not mean that *Blastocystis* has no importance in IBS, just that any role
48
49 appears not to be linked to a specific ST.
50
51
52
53

54 A difficulty with these studies is the suitability of the control groups used for comparison. In the
55
56 UK, the samples were all from a diagnostic laboratory and the vast majority of these will be from
57
58 individuals with gastrointestinal symptoms. There was a higher prevalence of ST4 in the samples
59
60
61
62
63
64
65

1
2
3 from IBS clinics in the UK although it did not reach statistical significance. It is interesting that
4
5 ST4 has been linked to non-IBS symptomatic infections in two other European studies (in Spain
6
7 and Denmark, mentioned above). However, a link between IBS and ST4 is not seen in Pakistan
8
9 or Egypt, where ST1 is significantly more common in IBS patients than controls.

10
11 It was noted earlier that studies in Egypt gave very different results depending on the subtyping
12
13 methodology used. It is possible that methodology could also be impacting on the IBS results
14
15 since the IBS studies in Egypt and Pakistan used STS typing while that in the UK used
16
17 sequencing to assign STs.
18
19
20
21
22
23

24 **4. Conclusion**

25
26 We have reinforced the emerging picture of substantial geographic variation in *Blastocystis* ST
27
28 distribution. The reasons underlying this variation are as yet unclear as in many studies little
29
30 demographic information has been gathered that might yield insights. In the future, sample
31
32 numbers for new surveys need to be greater than in the three pilot studies reported here, with
33
34 sampling in multiple geographically and climatically distinct sites where possible. Ideally, future
35
36 studies would also gather information on the individual's occupation and exposure to animals in
37
38 order to improve our understanding of the frequently postulated but unproven role of zoonotic
39
40 transmission. To eliminate uncertainty over the influence of methodology on ST results we
41
42 recommend the use of sequencing for assigning STs, despite this method's inability to identify
43
44 STs in mixed infections (Stensvold, in press).
45
46
47
48
49
50
51
52
53

54 **Acknowledgments**

55
56 We would like to thank the staff of the Diagnostic Parasitology Laboratory, LSHTM, for
57
58 providing the UK samples, the Sebha Central Medical Laboratory for providing the Libyan
59
60
61
62
63
64
65

1
2 samples, and the brothers of the Order of Saint John of God in Liberia for facilitating that study.
3
4
5 The UK and Libyan work formed part of the PhD thesis of MAA, who was supported by the
6
7 Libyan Government. The work was partly funded by the Danish Council for Independent
8
9 Research – Medical Sciences (Grant No. 271-09-0251), Danish Agency for Science Technology
10
11 and Innovation.
12
13
14
15
16

17 **References**

18
19 Alfellani, M.A., Khan, A.H., Al-Gazoui, R.M., Zaid, M.K., Al-Ferjani, M.A., 2007. Prevalence
20
21 and clinical features of *Blastocystis hominis* infection among patients in Sebha, Libya. Sultan
22
23 Qaboos Univ Med J, 7, 35-40.
24
25
26

27
28
29 Böhm-Gloning, B., Knobloch, J., Walderich, B., 1997. Five subgroups of *Blastocystis hominis*
30
31 from symptomatic and asymptomatic patients revealed by restriction site analysis of PCR-
32
33 amplified 16S-like rDNA. Trop Med Int Health 2, 771-778.
34
35
36

37
38
39 Clark, C.G., 1997. Extensive genetic diversity in *Blastocystis hominis*. Mol Biochem Parasitol
40
41 87, 79-83.
42
43
44

45
46 Clark, C.G., Diamond, L.S., 2002. Methods for cultivation of luminal parasitic protists of clinical
47
48 importance. Clin Microbiol Rev 15, 329-341.
49
50
51

52
53 Clark, C.G., van der Giezen, M., Alfellani, M.A., Stensvold, C.R. Recent developments in
54
55 *Blastocystis* research. Adv Parasitol (in press).
56
57
58
59
60
61
62
63
64
65

1
2
3 Dogruman-Al, F., Dagci, H., Yoshikawa, H., Kurt, O., Demirel, M., 2008. A possible link
4
5 between subtype 2 and asymptomatic infections of *Blastocystis hominis*. Parasitol Res 103, 685-
6
7 689.
8
9

10
11
12 Dogruman-Al, F., Kustimur, S., Yoshikawa, H., Tuncer, C., Simsek, Z., Tanyuksel, M., Araz, E.,
13
14 Boorum, K., 2009a. *Blastocystis* subtypes in irritable bowel syndrome and inflammatory bowel
15
16 disease in Ankara, Turkey. Mem Inst Oswaldo Cruz 104, 724-727.
17
18
19
20
21

22 Dogruman-Al, F., Yoshikawa, H., Kustimur, S., Balaban, N., 2009b. PCR-based subtyping of
23
24 *Blastocystis* isolates from symptomatic and asymptomatic individuals in a major hospital in
25
26 Ankara, Turkey. Parasitol Res 106, 263-268.
27
28
29
30
31

32 Domínguez-Márquez, M.V., Guna, R., Muñoz, C., Gómez-Muñoz, M.T., Borrás, R., 2009. High
33
34 prevalence of subtype 4 among isolates of *Blastocystis hominis* from symptomatic patients of a
35
36 health district of Valencia (Spain). Parasitol Res 105, 949-955.
37
38
39
40

41 Eroglu, F., Genc, A., Elgun, G., Koltas, I.S., 2009. Identification of *Blastocystis hominis* isolates
42
43 from asymptomatic and symptomatic patients by PCR. Parasitol Res 105, 1589-1592.
44
45
46
47
48

49 Eroglu, F., Koltas, I.S., 2010. Evaluation of the transmission mode of *B. hominis* by using PCR
50
51 method. Parasitol Res 107, 841-845.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 Forsell, J., Granlund, M., Stensvold, C.R., Clark, C.G., Evengård, B., 2012a. Erratum to:
4
5 Subtype analysis of *Blastocystis* isolates in Swedish patients. Eur J Clin Microbiol Infect Dis 31,
6
7 1697.
8
9

10
11
12 Forsell, J., Granlund, M., Stensvold, C.R., Clark, C.G., Evengård, B., 2012b. Subtype analysis of
13
14 *Blastocystis* isolates in Swedish patients. Eur J Clin Microbiol Infect Dis 31, 1689-1696.
15
16
17
18

19
20 Fouad, S.A., Basyoni, M.M., Fahmy, R.A., Kobaisi, M.H., 2011. The pathogenic role of different
21
22 *Blastocystis hominis* genotypes isolated from patients with irritable bowel syndrome. Arab J
23
24 Gastroenterol 12, 194-200.
25
26
27
28

29
30 Hussein, E.M., Hussein, A.M., Eida, M.M., Atwa, M.M., 2008. Pathophysiological variability of
31
32 different genotypes of human *Blastocystis hominis* Egyptian isolates in experimentally infected
33
34 rats. Parasitol Res 102, 853-860.
35
36
37
38

39
40 Jimenez-Gonzalez, D.E., Martinez-Flores, W.A., Reyes-Gordillo, J., Ramirez-Miranda, M.E.,
41
42 Arroyo-Escalante, S., Romero-Valdovinos, M., Stark, D., Souza-Saldivar, V., Martinez-
43
44 Hernandez, F., Flisser, A., Olivo-Diaz, A., Maravilla, P., 2012. *Blastocystis* infection is
45
46 associated with irritable bowel syndrome in a Mexican patient population. Parasitol Res 110,
47
48 1269-1275.
49
50
51
52

53
54 Jones, M.S., Whipps, C.M., Ganac, R.D., Hudson, N.R., Boorum, K., Boroom, K., 2009.
55
56 Association of *Blastocystis* subtype 3 and 1 with patients from an Oregon community presenting
57
58 with chronic gastrointestinal illness. Parasitol Res 104, 341-345.
59
60
61
62

1
2
3
4
5 Kaneda, Y., Horiki, N., Cheng, X.J., Fujita, Y., Maruyama, M., Tachibana, H., 2001. Ribodemes
6
7 of *Blastocystis hominis* isolated in Japan. Am J Trop Med Hyg 65, 393-396.
8
9

10
11
12 Lee, I.L., Tan, T.C., Tan, P.C., Nanthiney, D.R., Biraj, M.K., Surendra, K.M., Suresh, K.G.,
13
14 2012. Predominance of *Blastocystis* sp. subtype 4 in rural communities, Nepal. Parasitol Res
15
16 110, 1553-1562.
17
18
19
20
21

22 Leelayoova, S., Taamasri, P., Rangsin, R., Naaglor, T., Thathaisong, U., Mungthin, M., 2002. In-
23
24 vitro cultivation: a sensitive method for detecting *Blastocystis hominis*. Ann Trop Med Parasitol
25
26 96, 803-807.
27
28
29
30
31

32 Li, L.H., Zhang, X.P., Lv, S., Zhang, L., Yoshikawa, H., Wu, Z., Steinmann, P., Utzinger, J.,
33
34 Tong, X.M., Chen, S.H., Zhou, X.N., 2007a. Cross-sectional surveys and subtype classification
35
36 of human *Blastocystis* isolates from four epidemiological settings in China. Parasitol Res 102,
37
38 83-90.
39
40
41
42
43

44 Li, L.H., Zhou, X.N., Du, Z.W., Wang, X.Z., Wang, L.B., Jiang, J.Y., Yoshikawa, H.,
45
46 Steinmann, P., Utzinger, J., Wu, Z., Chen, J.X., Chen, S.H., Zhang, L., 2007b. Molecular
47
48 epidemiology of human *Blastocystis* in a village in Yunnan province, China. Parasitol Int 56,
49
50 281-286.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 Malheiros, A.F., Stensvold, C.R., Clark, C.G., Braga, G.B., Shaw, J.J., 2011. Short report:
3
4
5 Molecular characterization of *Blastocystis* obtained from members of the indigenous Tapirapé
6
7 ethnic group from the Brazilian Amazon region, Brazil. Am J Trop Med Hyg 85, 1050-1053.
8
9

10
11
12 Meloni, D., Sancier, G., Poirier, P., El Alaoui, H., Chabé, M., Delhaes, L., Dei-Cas, E., Delbac,
13
14 F., Luigi Fiori, P., Di Cave, D., Viscogliosi, E., 2011. Molecular subtyping of *Blastocystis* sp.
15
16 isolates from symptomatic patients in Italy. Parasitol Res 109, 613-619.
17
18
19
20
21

22 Menounos, P.G., Spanakos, G., Tegos, N., Vassalos, C.M., Papadopoulou, C., Vakalis, N.C.,
23
24 2008. Direct detection of *Blastocystis* sp. in human faecal samples and subtype assignment using
25
26 single strand conformational polymorphism and sequencing. Mol Cell Probes 22, 24-29.
27
28
29
30
31

32 Moosavi, A., Haghighi, A., Mojarad, E.N., Zayeri, F., Alebouyeh, M., Khazan, H., Kazemi, B.,
33
34 Zali, M.R., 2012. Genetic variability of *Blastocystis* sp. isolated from symptomatic and
35
36 asymptomatic individuals in Iran. Parasitol Res 111, 2311-2315.
37
38
39
40
41

42 Motazedian, H., Ghasemi, H., Sadjjadi, S.M., 2008. Genomic diversity of *Blastocystis hominis*
43
44 from patients in southern Iran. Ann Trop Med Parasitol 102, 85-88.
45
46
47
48

49 Nagel, R., Cuttall, L., Stensvold, C.R., Mills, P.C., Bielefeldt-Ohmann, H., Traub, R.J., 2012.
50
51 *Blastocystis* subtypes in symptomatic and asymptomatic family members and pets and response
52
53 to therapy. Intern Med J 42, 1187-1195.
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 Noël, C., Dufernez, F., Gerbod, D., Edgcomb, V.P., Delgado-Viscogliosi, P., Ho, L.C., Singh,
4
5 M., Wintjens, R., Sogin, M.L., Capron, M., Pierce, R., Zenner, L., Viscogliosi, E., 2005.

6
7 Molecular phylogenies of *Blastocystis* isolates from different hosts: implications for genetic
8
9 diversity, identification of species, and zoonosis. J Clin Microbiol 43, 348-355.

10
11
12
13
14 Noël, C., Peyronnet, C., Gerbod, D., Edgcomb, V.P., Delgado-Viscogliosi, P., Sogin, M.L.,
15
16 Capron, M., Viscogliosi, E., Zenner, L., 2003. Phylogenetic analysis of *Blastocystis* isolates from
17
18 different hosts based on the comparison of small-subunit rRNA gene sequences. Mol Biochem
19
20 Parasitol 126, 119-123.

21
22
23
24
25
26
27 Özyurt, M., Kurt, O., Mølbak, K., Nielsen, H.V., Haznedaroglu, T., Stensvold, C.R., 2008.
28
29 Molecular epidemiology of *Blastocystis* infections in Turkey. Parasitol Int 57, 300-306.

30
31
32
33
34 Petrášová, J., Uzlíková, M., Kostka, M., Petrželková, K.J., Huffman, M.A., Modrý, D., 2011.
35
36 Diversity and host specificity of *Blastocystis* in syntopic primates on Rubondo Island, Tanzania.
37
38 Int J Parasitol 41, 1113-1120.

39
40
41
42
43 Poirier, P., Wawrzyniak, I., Albert, A., El Alaoui, H., Delbac, F., Livrelli, V., 2011.
44
45 Development and evaluation of a real-time PCR assay for detection and quantification of
46
47 *Blastocystis* parasites in human stool samples: prospective study of patients with hematological
48
49 malignancies. J Clin Microbiol 49, 975-983.

50
51
52
53
54
55
56 Reinthaler, F.F., Mascher, F., Klem, G., Sixl, W., 1988. A survey of gastrointestinal parasites in
57
58 Ogun State, southwest Nigeria. Ann Trop Med Parasitol 82, 181-184.

1
2
3
4
5 Rene, B.A., Stensvold, C.R., Badsberg, J.H., Nielsen, H.V., 2009. Subtype analysis of
6
7 *Blastocystis* isolates from *Blastocystis* cyst excreting patients. Am J Trop Med Hyg 80, 588-592.
8
9

10
11
12 Rivera, W.L., Tan, M.A., 2005. Molecular characterization of *Blastocystis* isolates in the
13
14 Philippines by riboprinting. Parasitol Res 96, 253-257.
15
16
17
18

19
20 Roberts, T., Stark, D., Harkness, J., Ellis, J., 2012 Subtype distribution of *Blastocystis* isolates
21
22 identified in a Sydney population and pathogenic potential of *Blastocystis*. Eur J Clin Microbiol
23
24 Infect Dis (in press).
25
26
27
28

29
30 Santín, M., Gómez-Muñoz, M.T., Solano-Aguilar, G., Fayer, R., 2011. Development of a new
31
32 PCR protocol to detect and subtype *Blastocystis* spp. from humans and animals. Parasitol Res
33
34 109, 205-212.
35
36
37
38

39
40 Scanlan, P.D., Marchesi, J.R., 2008. Micro-eukaryotic diversity of the human distal gut
41
42 microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces.
43
44 ISME J 2, 1183-1193.
45
46
47
48

49
50 Scicluna, S.M., Tawari, B., Clark, C.G., 2006. DNA barcoding of *Blastocystis*. Protist 157, 77-
51
52 85.
53
54
55

56
57 Silberman, J.D., Sogin, M.L., Leipe, D.D., Clark, C.G., 1996. Human parasite finds taxonomic
58
59 home. Nature 380, 398.
60
61
62
63
64
65

1
2
3
4
5 Souppart, L., Moussa, H., Cian, A., Sanciu, G., Poirier, P., El Alaoui, H., Delbac, F., Boorom,
6
7 K., Delhaes, L., Dei-Cas, E., Viscogliosi, E., 2010. Subtype analysis of *Blastocystis* isolates from
8
9 symptomatic patients in Egypt. *Parasitol Res* 106, 505-511.
10
11

12
13
14 Souppart, L., Sanciu, G., Cian, A., Wawrzyniak, I., Delbac, F., Capron, M., Dei-Cas, E.,
15
16 Boorom, K., Delhaes, L., Viscogliosi, E., 2009. Molecular epidemiology of human *Blastocystis*
17
18 isolates in France. *Parasitol Res* 105, 413-421.
19
20
21

22
23
24 Stark, D., van Hal, S., Marriott, D., Ellis, J., Harkness, J., 2007. Irritable bowel syndrome: a
25
26 review on the role of intestinal protozoa and the importance of their detection and diagnosis. *Int J*
27
28 *Parasitol* 37, 11-20.
29
30
31

32
33
34 Stensvold, C.R., Comparison of sequencing (barcode region) and STS PCR for *Blastocystis*
35
36 subtyping. *J Clin Microbiol* (in press).
37
38
39

40
41 Stensvold, C.R., Arendrup, M.C., Jespersgaard, C., Mølbak, K., Nielsen, H.V., 2007. Detecting
42
43 *Blastocystis* using parasitologic and DNA-based methods: a comparative study. *Diagn Microbiol*
44
45 *Infect Dis* 59, 303-307.
46
47
48

49
50
51 Stensvold, C.R., Christiansen, D.B., Olsen, K.E., Nielsen, H.V., 2011a. *Blastocystis* sp. subtype
52
53 4 is common in Danish *Blastocystis*-positive patients presenting with acute diarrhea. *Am J Trop*
54
55 *Med Hyg* 84, 883-885.
56
57
58

1
2
3 Stensvold, C.R., Lewis, H.C., Hammerum, A.M., Porsbo, L.J., Nielsen, S.S., Olsen, K.E.,
4
5 Arendrup, M.C., Nielsen, H.V., Mølbak, K., 2009. *Blastocystis*: unravelling potential risk factors
6
7 and clinical significance of a common but neglected parasite. *Epidemiol Infect* 137, 1655-1663.
8
9

10
11
12 Stensvold, C.R., Nielsen, S.D., Badsberg, J.H., Engberg, J., Friis-Møller, N., Nielsen, S.S.,
13
14 Nielsen, H.V., Friis-Møller, A., 2011b. The prevalence and clinical significance of intestinal
15
16 parasites in HIV-infected patients in Denmark. *Scand J Infect Dis* 43, 129-135.
17
18
19
20
21

22 Stensvold, R., Brillowska-Dabrowska, A., Nielsen, H.V., Arendrup, M.C., 2006. Detection of
23
24 *Blastocystis hominis* in unpreserved stool specimens by using polymerase chain reaction. *J*
25
26 *Parasitol* 92, 1081-1087.
27
28
29
30
31

32 Tan, K.S., 2008. New insights on classification, identification, and clinical relevance of
33
34 *Blastocystis* spp. *Clin Microbiol Rev* 21, 639-665.
35
36
37
38

39 Tan, T.C., Ong, S.C., Suresh, K.G., 2009. Genetic variability of *Blastocystis* sp. isolates obtained
40
41 from cancer and HIV/AIDS patients. *Parasitol Res* 105, 1283-1286.
42
43
44
45

46 Tan, T.C., Suresh, K.G., Smith, H.V., 2008. Phenotypic and genotypic characterisation of
47
48 *Blastocystis hominis* isolates implicates subtype 3 as a subtype with pathogenic potential.
49
50
51 *Parasitol Res* 104, 85-93.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 Thathaisong, U., Worapong, J., Mungthin, M., Tan-Ariya, P., Viputtigul, K., Sudatis, A.,
4
5 Noonai, A., Leelayoova, S., 2003. *Blastocystis* isolates from a pig and a horse are closely related
6
7 to *Blastocystis hominis*. J Clin Microbiol 41, 967-975.
8
9

10
11
12 Ustun, S., Turgay, N., 2006. [*Blastocystis hominis* and bowel diseases]. Turkiye Parazitoloj Derg
13
14 30, 72-76.
15
16
17
18

19
20 Wong, K.H., Ng, G.C., Lin, R.T., Yoshikawa, H., Taylor, M.B., Tan, K.S., 2008. Predominance
21
22 of subtype 3 among *Blastocystis* isolates from a major hospital in Singapore. Parasitol Res 102,
23
24 663-670.
25
26
27
28

29
30 Yakoob, J., Jafri, W., Beg, M.A., Abbas, Z., Naz, S., Islam, M., Khan, R., 2010. Irritable bowel
31
32 syndrome: is it associated with genotypes of *Blastocystis hominis*. Parasitol Res 106, 1033-1038.
33
34
35
36

37 Yakoob, J., Jafri, W., Jafri, N., Khan, R., Islam, M., Beg, M.A., Zaman, V., 2004. Irritable bowel
38
39 syndrome: in search of an etiology: role of *Blastocystis hominis*. Am J Trop Med Hyg 70, 383-
40
41 385.
42
43
44
45

46
47 Yan, Y., Su, S., Lai, R., Liao, H., Ye, J., Li, X., Luo, X., Chen, G., 2006. Genetic variability of
48
49 *Blastocystis hominis* isolates in China. Parasitol Res 99, 597-601.
50
51
52
53

54
55 Yoshikawa, H., Abe, N., Iwasawa, M., Kitano, S., Nagano, I., Wu, Z., Takahashi, Y., 2000.
56
57 Genomic analysis of *Blastocystis hominis* strains isolated from two long-term health care
58
59 facilities. J Clin Microbiol 38, 1324-1330.
60
61
62
63
64
65

1
2
3
4
5 Yoshikawa, H., Nagano, I., Wu, Z., Yap, E.H., Singh, M., Takahashi, Y., 1998. Genomic
6
7 polymorphism among *Blastocystis hominis* strains and development of subtype-specific
8
9 diagnostic primers. Mol Cell Probes 12, 153-159.
10

11
12
13
14
15 Yoshikawa, H., Wu, Z., Kimata, I., Iseki, M., Ali, I.K., Hossain, M.B., Zaman, V., Haque, R.,
16
17 Takahashi, Y., 2004. Polymerase chain reaction-based genotype classification among human
18
19 *Blastocystis hominis* populations isolated from different countries. Parasitol Res 92, 22-29.
20
21

22
23
24 Yoshikawa, H., Wu, Z., Pandey, K., Pandey, B.D., Sherchand, J.B., Yanagi, T., Kanbara, H.,
25
26 2009. Molecular characterization of *Blastocystis* isolates from children and rhesus monkeys in
27
28 Kathmandu, Nepal. Vet Parasitol 160, 295-300.
29
30

31
32
33
34
35
36
37 Figure legend.
38

39
40
41 Figure 1. Relative distribution of *Blastocystis* STs across various major geographic regions. The
42
43 geographic summary data listed in Table 2 are depicted graphically as a percentage of total
44
45 samples subtyped for each region.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1
[Click here to download high resolution image](#)




Table 1

Host	Subtype								Total
	ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8	
IBS	14 (10.3 %)	10 (7.4 %)	56 (41.2 %)	51 (37.5 %)	-	1 (0.7 %)	1 (0.7 %)	3 (2.2 %)	136
Unselected	20 (14.8 %)	16 (11.9 %)	58 (42.9 %)	34 (25.2 %)	2 (1.5 %)	-	3 (2.2 %)	2 (1.5 %)	135
Total	34 (12.5%)	26 (9.6%)	114 (42.1%)	85 (31.4%)	2 (0.7%)	1 (0.4%)	4 (1.5%)	5 (1.8%)	271

Table 1. Comparison of *Blastocystis* subtype distribution in IBS clinic- and physician-submitted sample groups in the UK.

Table 2

Country of sample origin	Technique#	No. of subtype observations	Subtype distribution											Reference
			ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8	ST9	Mixed ST	Unknown	
Brazil	Sequencing	73	33	27	13	—	—	—	—	—	—	7	—	Malheiros et al., 2011
Colombia	Sequencing	13	5	4	4	—	—	—	—	—	—	1	—	Santin et al., 2011
USA	Sequencing	7	1	—	6	—	—	—	—	—	—	—	—	Jones et al., 2009
AMERICAS TOTAL		93	39	31	23	0	0	0	0	0	0	8	0	
Denmark	Sequencing	29	1	6	15	7	—	—	—	—	—	—	—	Stensvold et al., 2006
Denmark	Sequencing	28	5	9	13	1	—	—	—	—	—	—	—	Stensvold et al., 2007
Denmark	Sequencing	92	20	15	39	16	—	1	—	1	—	7	—	Rene et al., 2009
Denmark	Sequencing	143	31	39	42	24	—	—	6	—	1	26	—	Stensvold et al., 2009
Denmark	Sequencing	25	1	4	1	19	—	—	—	—	—	—	—	Stensvold et al., 2011a
Denmark	Sequencing	24	11	—	13	—	—	—	—	—	—	2	—	Stensvold et al., 2011b
France	Sequencing	43	11	4	23	4	—	—	1	—	—	3	—	Souppart et al., 2009
France	Sequencing	27	1	1	4	17	—	1	3	—	—	—	—	Poirier et al., 2011
Germany	RFLP	171	40	1	118	12	—	—	—	—	—	8	—	Böhm-Gloning et al., 1997
Germany	STS	12	3	2	5	2	—	—	—	—	—	—	—	Yoshikawa et al., 2004
Greece	SSCP	45	9	6	27	1	—	1	1	—	—	—	—	Menounos et al., 2008
Ireland	Sequencing	14	1	6	4	3	—	—	—	—	—	—	—	Scanlan and Marchesi, 2008
Italy	Sequencing	34	3	7	16	6	—	—	1	1	—	4	—	Meloni et al., 2011
Spain	RFLP	51	1	2	—	48	—	—	—	—	—	—	—	Dominguez-Márquez et al., 2009
Sweden	Sequencing	63	10	9	30	13	—	—	1	—	—	—	—	Forsell et al., 2012a&b
UK	RFLP	29	2	1	22	4	—	—	—	—	—	—	—	Clark, 1997
UK	Sequencing	48	2	8	20	16	—	—	1	1	—	1	—	Scicluna et al., 2006
UK	Sequencing	271	34	26	114	85	2	1	4	5	—	—	—	Present study
EUROPE TOTAL		1149	186	146	506	278	2	4	18	8	1	51	0	
Egypt	STS	110	15	—	49	—	—	33	13	—	—	10	—	Fouad et al., 2011
Egypt	STS	44	8	—	24	—	—	8	4	—	—	—	—	Hussein et al., 2008
Egypt	Sequencing	21	4	4	13	—	—	—	—	—	—	1	—	Souppart et al., 2010
Liberia	Sequencing	25	7	7	8	3	—	—	—	—	—	5	—	Present study
Libya	Sequencing	38	19	3	15	—	—	—	1	—	—	—	—	Present study
Nigeria	Sequencing	22	10	—	9	3	—	—	—	—	—	1	—	Present study
Tanzania	Sequencing	6	1	3	2	—	—	—	—	—	—	—	—	Petrásová et al., 2011
AFRICA TOTAL		266	64	17	120	6	0	41	18	0	0	17	0	
Bangladesh	STS	26	2	—	24	—	—	—	—	—	—	—	—	Yoshikawa et al., 2004
Iran	RFLP	40	20	4	16	—	—	—	—	—	—	—	5	Motazedian et al., 2008
Iran	STS	141	48	33	53	—	—	—	7	—	—	33	—	Moosavi et al., 2012
Nepal	STS	20	4	4	12	—	—	—	—	—	—	—	—	Yoshikawa et al., 2009
Nepal	STS	101	40	—	—	—	—	8	53	—	—	41	8	Lee et al., 2012
Pakistan	STS	10	2	—	7	—	—	1	—	—	—	—	—	Yoshikawa et al., 2004
Pakistan	STS	177	87	10	49	8	7	6	10	—	—	—	2	Yakoob et al., 2010
Turkey	Sequencing	87	8	12	66	1	—	—	—	—	—	—	—	Özyurt et al., 2008
Turkey	STS	96	19	22	55	—	—	—	—	—	—	4	—	Dogruman-AI et al., 2008
Turkey	STS	32	20	3	9	—	—	—	—	—	—	—	—	Eroglu et al., 2009
Turkey	STS	38	3	13	22	—	—	—	—	—	—	3	—	Dogruman-AI et al., 2009a
Turkey	STS	75	19	11	45	—	—	—	—	—	—	9	—	Dogruman-AI et al., 2009b
Turkey	STS	25	9	6	10	—	—	—	—	—	—	—	—	Eroglu and Koltas, 2010
CENTRAL ASIA TOTAL		868	281	118	368	9	7	15	70	0	0	90	15	
China	STS	38	17	—	19	—	—	—	2	—	—	5	1	Yan et al., 2006
China	STS	194	56	11	125	1	—	1	—	—	—	10	8	Li et al., 2007a
China	STS	76	18	1	56	1	—	—	—	—	—	2	3	Li et al., 2007b
Japan	STS	32	1	—	30	—	—	1	—	—	—	—	—	Yoshikawa et al., 2000
Japan	RFLP	61	11	13	30	7	—	—	—	—	—	—	3	Kaneda et al., 2001
Japan	STS	50	4	—	26	2	—	11	5	—	2	—	—	Yoshikawa et al., 2004
Malaysia	STS	20	9	1	10	—	—	—	—	—	—	—	—	Tan et al., 2008
Malaysia	STS	38	5	—	20	—	—	11	2	—	—	—	2	Tan et al., 2009
Philippines	RFLP	10	10	—	—	—	—	—	—	—	—	—	2	Rivera and Tan, 2005
Singapore	RFLP	9	2	—	7	—	—	—	—	—	—	—	—	Wong et al., 2008
Thailand	RFLP	159	144	—	13	—	—	—	2	—	—	6	—	Thathaisong et al., 2003
Thailand	STS	5	2	—	2	—	—	1	—	—	—	1	—	Yoshikawa et al., 2004
E & SE-ASIA TOTAL		692	279	26	338	11	0	25	11	0	2	24	19	
Australia	Sequencing	12	5	—	4	2	—	1	—	—	—	1	—	Nagel et al., 2012
Australia	Sequencing	91	28	5	40	12	—	3	1	2	—	—	—	Roberts et al., 2012
AUSTRALIA TOTAL		103	33	5	44	14	0	4	1	2	0	1	0	
EARTH	Total	3171	882	343	1399	318	9	89	118	10	3	191	34	

Table 2. Subtype distribution by country of sample origin.

STS= Sequence-tagged site; RFLP=Restriction fragment length polymorphism; SSCP=Single strand conformation polymorphism

Table 3

Country	Subtype									χ^2 and Fisher's Exact Test results						Reference
	ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8		UK	Libya	Liberia	Nigeria	Egypt1	Egypt2	
UK	34 (12.5%)	26 (9.6%)	114 (42.1%)	85 (31.4%)	2 (0.7%)	1 (0.4%)	4 (1.5%)	5 (1.8%)	271							Present study
Libya	19 (50%)	3 (7.9%)	15 (39.5%)	-	-	-	1 (2.6%)	-	38	P= <0.0001						Present study
Liberia	7 (28.0%)	7 (28.0%)	8 (32.0%)	3 (12.0%)	-	-	-	-	25	P= 0.022	P= 0.026					Present study
Nigeria	10 (45.5%)	-	9 (40.9%)	3 (13.6%)	-	-	-	-	22	P=0.005	P= 0.140	P= 0.059				Present study
Egypt 1	8 (18.2%)	-	24 (54.5%)	-	-	8 (18.2%)	4 (9.1%)	-	44	P= <0.0001	P= <0.001	P= <0.0001	P= 0.002			Hussein et al., 2008
Egypt 2	3 (15.8%)	4 (20.1%)	12 (63.2%)	-	-	-	-	-	19	P= 0.140	P= 0.026	P= 0.139	P= 0.012	P= 0.005		Souppart et al., 2010
Egypt 3	15 (16.7%)	-	39 (43.3%)	-	-	23 (25.6%)	13 (14.4%)	-	90	P= <0.0001	P= <0.0001	P= <0.0001	P= <0.0001	P= 0.534	P= <0.0001	Fouad et al., 2011
Total	96	40	221	91	2	32	22	5	509							

Table 3. Comparison of *Blastocystis* subtype distribution in some African countries and the UK. The Tanzanian study (Petrášová et al., 2011) was not included due to small numbers. The subtype distributions were compared using the χ^2 or Fisher's Exact Test as appropriate.

Table 4

Country	Subtype										Total	Reference
	ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8	Mixed ST	Unidentified ST		
Pakistan	75 (61%)	6 (4.9%)	23 (18.7%)	6 (4.9%)	3 (2.4%)	3 (2.4%)	5 (4.1%)	-	-	2 (1.6%)	123	Yakoob et al., 2010
Egypt	15 (29.4%)	-	22 (43.1%)	-	-	8 (15.7%)	-	-	6 (11.8%)	-	51	Fouad et al., 2011
UK	14 (10.3%)	10 (7.4%)	56 (41.2%)	51 (37.5%)	-	1 (0.7%)	1 (0.7%)	3 (2.2%)	-	-	136	Present study
Total	104	16	101	57	3	12	6	3	6	2	310	

Table 4. Distribution of *Blastocystis* subtypes in IBS clinic samples from different countries.

Table 5

Country	Subtype										Total	Reference
	ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8	Mixed ST	Unidentified ST		
Pakistan	12 (21.4%)	4 (7.1%)	26 (46.4%)	2 (3.6%)	4 (7.1%)	3 (5.4%)	5 (8.9%)	–	–	–	56	Yakoob et al., 2010
Egypt	–	–	17 (34.7%)	–	–	15 (30.6%)	13 (26.5%)	–	4 (8.2%)	–	49	Fouad et al., 2011
UK	20 (14.8%)	16 (11.9%)	58 (42.9%)	34 (25.2%)	2 (1.5%)	–	3 (2.2%)	2 (1.5%)	–	–	135	Present study
Total	32	20	101	36	6	18	21	2	4	–	240	

Table 5. Distribution of *Blastocystis* subtypes in control groups from IBS studies in different countries.